Key statistics
52-week range
Open | 1.03 |
---|---|
High | 1.03 |
Low | 1.03 |
Bid | 1.06 |
Offer | 1.10 |
Previous close | 1.02 |
Average volume | 0.00 |
---|---|
Shares outstanding | 39.41m |
Free float | 37.36m |
P/E (TTM) | -- |
Market cap | 47.30m USD |
EPS (TTM) | -1.65 USD |
Data delayed at least 15 minutes, as of Sep 26 2024 07:12 BST.
More ▼
Announcements
- Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
- Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
- Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
- Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
- Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
- Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
- Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
- Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
More ▼